Neurocrine Posts Strong Q1 as Key Treatments Drive Growth, Morgan Stanley Says

MT Newswires Live05-06

Neurocrine Biosciences (NBIX) delivered a strong Q1, powered by rising demand for Ingrezza, its leading treatment for involuntary muscle movements, and an encouraging early launch of Crenessity, a new hormone-related therapy, Morgan Stanley said Wednesday in a report.

Ingrezza demand is tracking above the company's 2026 guidance, supported by record new patient starts, durable persistence and no inventory effects or other one-time items in the quarter, the report said.

Crenessity is a "definitive blockbuster in the making" with current sales reflecting only a fraction of its eventual potential as the launch remains early, Morgan Stanley said.

Neurocrine's acquisition of Soleno Therapeutics (SLNO) is expected to close around July 6, the report said.

Morgan Stanley raised its price target on Neurocrine stock to $191 from $185 and maintained its equal-weight rating.

Price: 145.19, Change: +10.13, Percent Change: +7.50

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2633137816?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 23:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633137816","market":"us","top_or_hot":-1,"title":"Neurocrine Posts Strong Q1 as Key Treatments Drive Growth, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> Neurocrine Biosciences (NBIX) delivered a strong Q1, powered by rising demand for  Ingrezza, its leading treatment for involuntary muscle movements, and an encouraging early launch of Crenessity, a new hormone-related therapy, Morgan Stanley said Wednesday in a report.</p><p>Ingrezza demand is tracking above the company's 2026 guidance, supported by record new patient starts, durable persistence and no inventory effects or other one-time items in the quarter, the report said.</p><p>Crenessity is a \"definitive blockbuster in the making\" with current sales reflecting only a fraction of its eventual potential as the launch remains early, Morgan Stanley said.</p><p>Neurocrine's acquisition of <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a> (SLNO) is expected to close around July 6, the report said.</p><p>Morgan Stanley raised its price target on Neurocrine stock to $191 from $185 and maintained its equal-weight rating.</p><p>Price: 145.19, Change: +10.13, Percent Change: +7.50</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurocrine Posts Strong Q1 as Key Treatments Drive Growth, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurocrine Posts Strong Q1 as Key Treatments Drive Growth, Morgan Stanley Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-06 23:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Neurocrine Biosciences (NBIX) delivered a strong Q1, powered by rising demand for  Ingrezza, its leading treatment for involuntary muscle movements, and an encouraging early launch of Crenessity, a new hormone-related therapy, Morgan Stanley said Wednesday in a report.</p><p>Ingrezza demand is tracking above the company's 2026 guidance, supported by record new patient starts, durable persistence and no inventory effects or other one-time items in the quarter, the report said.</p><p>Crenessity is a \"definitive blockbuster in the making\" with current sales reflecting only a fraction of its eventual potential as the launch remains early, Morgan Stanley said.</p><p>Neurocrine's acquisition of <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a> (SLNO) is expected to close around July 6, the report said.</p><p>Morgan Stanley raised its price target on Neurocrine stock to $191 from $185 and maintained its equal-weight rating.</p><p>Price: 145.19, Change: +10.13, Percent Change: +7.50</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0795875086.SGD","symbol_name":"JPMorgan Investment Funds - Global Income A (div) SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2633137816","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633137816","pubTimestamp":1778081152,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neurocrine Biosciences  delivered a strong Q1, powered by rising demand for  Ingrezza, its leading treatment for involuntary muscle movements, and an encouraging early launch of Crenessity, a new hormone-related therapy, Morgan Stanley said Wednesday in a report.Ingrezza demand is tracking above the company's 2026 guidance, supported by record new patient starts, durable persistence and no inventory effects or other one-time items in the quarter, the report said.Crenessity is a \"definitive blockbuster in the making\" with current sales reflecting only a fraction of its eventual potential as the launch remains early, Morgan Stanley said.Neurocrine's acquisition of Soleno Therapeutics  is expected to close around July 6, the report said.Morgan Stanley raised its price target on Neurocrine stock to $191 from $185 and maintained its equal-weight rating.Price: 145.19, Change: +10.13, Percent Change: +7.50","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","BK4127":"投资银行业与经纪业","BK4139":"生物科技","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","BK4516":"特朗普概念","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU1732800096.USD":"摩根大通环球收益基金A (irc)","NBIX":"神经分泌生物科学","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","BK4588":"碎股","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0557290698.USD":"施罗德环球可持续增长基金","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","MS":"摩根士丹利","SLNO":"Soleno Therapeutics","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0971096721.USD":"富达环球金融服务 A","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU0106831901.USD":"贝莱德世界金融基金A2","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","BK4581":"高盛持仓","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"摩根士丹利表示，由于关键治疗方法推动增长，Neurocrine第一季度表现强劲","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":1,"MS":0.9,"SLNO":1},"content_text":"Neurocrine Biosciences (NBIX) delivered a strong Q1, powered by rising demand for  Ingrezza, its leading treatment for involuntary muscle movements, and an encouraging early launch of Crenessity, a new hormone-related therapy, Morgan Stanley said Wednesday in a report.Ingrezza demand is tracking above the company's 2026 guidance, supported by record new patient starts, durable persistence and no inventory effects or other one-time items in the quarter, the report said.Crenessity is a \"definitive blockbuster in the making\" with current sales reflecting only a fraction of its eventual potential as the launch remains early, Morgan Stanley said.Neurocrine's acquisition of Soleno Therapeutics (SLNO) is expected to close around July 6, the report said.Morgan Stanley raised its price target on Neurocrine stock to $191 from $185 and maintained its equal-weight rating.Price: 145.19, Change: +10.13, Percent Change: +7.50","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633137816","isCrawlerRequest":true}